• There was substantial geographic variation in the diagnostic interval and in the use of Diagnostic Assessment Unit (DAU) services across Ontario.
by organized programs. 3 But a high screening participation rate does not necessarily mean that all breast cancers are detected by the screening program. In fact, many are detected when the patient presents to her doctor with breast cancer signs or symptoms. 4 Documentation of the proportion of breast cancer patients detected by screening (vs. symptomatic presentation) is lacking.
The breast cancer diagnostic period is characterized by multiple appointments for diagnostic tests and consultations and it often provokes considerable distress and anxiety for women and their families. [5] [6] [7] A diagnostic delay of three months or more can lead to advanced cancer stage and lower chances of survival. 8 The 2007 guideline for monitoring breast screening program performance recommended 90% of abnormal screening results should be
Introduction
Screening is important for achieving an early diagnosis of cancer and thereby improving the chance of survival. 1 In Canada, mammograms for breast cancer screening resolved within 5 weeks, or within 7 weeks if a tissue (core or open) biopsy is required. 9 Consequently, the time interval from an abnormal screen to a final diagnosis is routinely assessed against the national targets by organized programs. In 2011, the Ontario Breast Screening Program (OBSP) reported significant regional variation in meeting the national timeliness target for women with abnormal screens. 3 However, little is known about the length of the diagnostic interval at the population level and whether it varies in different regions of the province.
Ontario Diagnostic Assessment Units (DAUs) are innovative, facility-based programs designed to improve the timeliness and quality of diagnostic care services. 7 Similar initiatives exist in many jurisdictions around the world. 10, 11 Ontario breast DAUs take two forms: organized Breast Assessment Affiliates (BAAs), 12 and regionally developed breast assessment centres. Diagnostic care at BAAs is provided by a multidisciplinary health care team that includes a nurse navigator who coordinates the process. This differs from the usual care diagnostic route (UC) where the patient's primary care provider plays a central role in arranging referrals and recommending appropriate diagnostic assessments and specialist consultations. [12] [13] [14] The nurse navigator also provides patient psychological and informational support. Each designated facility has to meet minimum organizational criteria regarding breast cancer diagnostic service resources and availability to maintain its BAA status. 13 The diagnostic process at regional breast assessment centres is less well documented, but those centres have similar goals and structures to those of the BAAs.
This study aimed to describe, among all Ontario breast cancer patients: 1) the cancer detection method; 2) the length of the diagnostic interval and its geographic pattern; and 3) the coverage of DAU services and its geographic pattern. This is one of three reports arising from our populationbased study on DAU use and the diagnostic interval.
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Methods
Study population
The study population consisted of women with a first primary invasive breast cancer diagnosed in 2011 in Ontario, Canada. We excluded: 1) those whose cancer registry record could not be linked to administrative data; 2) those who were living outside of Ontario at the time of diagnosis; and 3) those who did not have Ontario Health Insurance Plan (OHIP) coverage for at least three years prior to diagnosis.
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Data sources
Study data included the Ontario Cancer Registry linked to administrative databases at the Institute for Clinical Evaluative Sciences (ICES) and Cancer Care Ontario (CCO). We used the Ontario Cancer Registry to identify breast cancer cases and determine the date of diagnosis. The Collaborative Stage Data provided information on cancer stage and histology. We defined stage at diagnosis using the TNM classification, 7th edition. 17, 18 The OBSP database provides information on screening date, screening test results and use of BAAs. The OHIP claims database, the National Ambulatory Care Reporting System (NACRS), the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and the Same-Day Surgery Database (CIHI-SDS) contain information on breast cancer diagnostic procedures and associated dates and physicians. A list of BAA hospitals was provided by the OBSP and we developed a separate list of regional breast assessment centres by conducting an email survey among CCO Regional Primary Care Leads and OBSP Regional Program Managers.
Detection method, diagnostic interval and DAU use definitions
We determined screen-detected cancers by looking back 12 months from the date of the cancer diagnosis for abnormal OBSP screens and 6 months for opportunistic screens. We assumed a patient presented with signs or symptoms if her cancer was not screen-detected. We shortened the look-back time window to 6 months from 12 months when identifying opportunistic screens because those screens were identified using billing claims, which do not contain test results (which were available in the OBSP database). This 6-month window was based on Canadian guideline evidence 9, 19 and our observation that fewer than 5% of abnormal OBSP screens occurred in the 6 to 12 months before diagnosis. 15 We defined the diagnostic interval as the number of days from the date of the cancer diagnosis back to the initial screen, or referral to a specialist or the first diagnostic test in the absence of a screening test (Figure 1 ). This strategy is an adaptation of one used in colorectal cancer. 20 The cancer diagnosis date was contained in the Ontario Cancer Registry and is normally the first occurrence of a histologyor cytology-confirmed malignancy or a hospital admission or outpatient consultation. The diagnostic interval was analyzed as both a continuous and a dichotomous outcome at 7 weeks, with the latter based on the longer of the two timeliness targets mentioned above. 9, 19 We determined DAU use for patients who had an initial screen within the OBSP (OBSP patients) separately from the rest, because the OBSP has a database that tracks the use of the Breast Assessment Affiliates. The OBSP patients were considered to be diagnosed through a DAU if they had either an OBSP BAA payment record or a biopsy/surgery performed at a DAU hospital. Otherwise, they were considered to be diagnosed through the UC. The remaining patients (opportunistically screened and symptomatic patients) were considered to be diagnosed through a DAU if they had a biopsy/surgery performed at a DAU hospital. We validated this strategy using the OBSP record as the criterion standard and found that using the biopsy/surgery hospital had a sensitivity of 90.1% and a specificity of 84.6%. 15 
Statistical analysis
We used proportions to describe the breast cancer screening detection rates and DAU use. Screening detection rates were categorized into three age groups (< 50 years, 50-69 years, > 69 years) based on the most recent Canadian guideline at the time of this study, although the updated guideline increased the upper age limit for screening to 74 in November of 2011. 21 We report the median diagnostic interval because its distribution is right-skewed. We report the diagnostic interval and DAU coverage by Local Health Integration Network (LHIN) and by county, both based on the patient's residence location at diagnosis. The county-level diagnostic interval was categorized for mapping purposes with category cut-points chosen to ensure a reasonable number of counties within each category. DAU service coverage was also categorized for mapping. To assess whether adjacent counties could be combined, we calculated a spatial autocorrelation on the diagnostic interval using the Global Moran's I statistic, which takes the values between −1 (perfect spatial dispersion) to 1 (perfect spatial clustering), with 0 representing a random geographic pattern. 22 For the county-level analysis, we conducted univariable and multivariable median regressions to assess the unadjusted and stage-adjusted geographic variation in the diagnostic interval because earlier stage at diagnosis has repeatedly been shown to be associated with a longer diagnostic interval. 23 We received ethics approval from the Health Sciences and Affiliated Teaching Hospitals Research Ethics Board at Queen's University at Kingston, Ontario, Canada.
Results
The final cohort size was 6898. The flow chart depicting the cohort selection process is shown in Figure 2 . The mean age was 61.2 (SD: 13.5).
Of the 6898 patients, 2499 (36.2%) were screen-detected and 4399 (63.8%) were symptomatic. Table 1 reports screening detection rates by age group. Of screendetected patients, 1986 (79.5%) were screened via the OBSP and 513 (20.5%) were screened opportunistically.
The provincial median time to diagnosis was 32 days (interquartile range: 17-60). Sixty-eight percent of breast cancer patients were diagnosed within the 7-week target, while 10% waited 107 days or more. Nearly half (48.4%) of patients were diagnosed at a DAU. Table 2 describes the diagnostic interval and DAU use by LHIN. The median diagnostic interval ranged from 24 days (95% CI: 20.6-27.4) in the South East LHIN to 41 days (95% CI: 34.7-47.3) in the North West LHIN (p < .001). The percent of women diagnosed through a DAU varied from 2.6% (95% CI: 0.7%-4.6%) in the North Simcoe Muskoka LHIN to 93% (95% CI: 90.2%-95.8%) in the South East LHIN (p < .001), reflecting regional differences in DAU availability. There was no evidence of a spatial correlation in the diagnostic interval (Global Moran's I = −0.02, p = .95), indicating that grouping neighbouring counties, as is done when reporting by LHIN, masks variation. Counties with the longest diagnostic intervals were scattered across the province, and patients in the most populous area (Greater Toronto Area) experienced waits in the second longest category. As Table 3 shows, 13 counties out of 47 (two counties with small numbers are not reported) had a median diagnostic interval greater than 7 weeks, and the median ranged from 15 days (95% CI: 7.6-22.4) to 65 days (95% CI: 39.6-90.4). This variation did not materially change with stage adjustment (results not shown). Figure 4 maps county-level DAU service use across Ontario. Rates range from 0% to 100%, partially reflecting that, at the time of this study, DAUs did not exist in 19 (38.8%) counties (see Table 3 ). Of these 19, 11 had a median diagnostic interval 29 The only other Canadian evidence on the breast cancer screening detection rate comes from two recent studies in Alberta, with one reporting that 44% of all breast cancers were detected through screening from 2007 to 2010 24 and the other reporting a screening detection rate of 38% from 2004 to 2010 25 (we observed 36% in Ontario in 2011). Screening eligibility criteria differ between the two provinces, as the Alberta Breast Cancer Screening Program additionally accepts patients aged 40 to 49 years. 30 However, the biennial breast cancer screening participation rate (programmatic and nonprogrammatic) for women aged 50 to 69 years is lower in Alberta (55.1%-57.3% in 2007-2010) 31 than Ontario (66.3% in years 2007-2008). 27 Two population-based studies conducted in United States reported the proportions of screen-detected cancer at 22% and 30.2%, respectively, 32, 33 with the latter restricted to women aged 40 to 49 years. These lower rates may have changed since these studies were conducted in the 1990s. A more recent study in Mexico 34 reported a screening detection rate of greater than or equal to the provincial median.
Discussion
To the best of our knowledge, this is the first Ontario study and among the first Canadian studies describing breast cancer screening detection rates and waiting time to diagnosis in a population-based breast cancer cohort. 24, 25 Previous Ontario reports have been restricted to those seen within organized breast cancer screening programs 12,26 while our study also includes the 63.8% of breast cancer patients who were diagnosed symptomatically and the 7.4% detected through opportunistic screening.
Our observed screening detection rate (48.4% in those breast cancer patients aged 50-69 years) was lower than the general population screening participation rates reported by the OBSP. In calendar years 2007 and 2008, the OBSP calculated that 66.3% of the Ontario women aged 50 to 69 years had been screened (through OBSP or opportunistic screening), 27 and the coverage was estimated to be similar in 2011. 3 The discrepancy between screening program participation rates and screening detection rates aligns with evidence that those at higher risk with breast cancer risk factors such as higher age and lack of exercise are less likely to get screened 28 and that some women are being diagnosed between screenings. To this latter point, Kirsh et study is required to better understand these differences.
Compared to the LHIN-level analysis, we observed greater variation between counties; there was a maximum difference of 7.1 weeks (50 days) between counties, indicating intra-LHIN variation. Consistent with the LHIN-level findings, the longest diagnostic intervals were observed in both the most populous (Greater Toronto Area) and the least populous (northern Ontario) areas. We also observed significant variation in DAU service use across counties. The county with 0% of DAU use had the longest diagnostic interval at both the median (65 days) and 75th percentile (108 days), and the county where 100% of patients used DAU service had a median diagnostic interval (27 days) that was among the shortest.
We previously hypothesized that the variation in the diagnostic interval may be partially attributable to different DAU service availabilities across regions. 14, 15 We found that DAU use was associated with reduced time-to-diagnosis for both screendetected and symptomatic patients after control for potential confounders in multivariable analyses. 14, 16 It should be noted that other regional factors such as patient demographics, care referral processes and local programs may have contributed to the variation that we have observed, since regions with high DAU coverage are not consistently associated with shorter diagnostic intervals. The World Health Organization has identified geographic variation as a health care quality concern pertinent to two dimensions: equity and accessibility. 35 Therefore, the reasons for this observed variation warrant further investigation in order to improve access and equity of breast cancer diagnostic care.
Strengths and limitations
This study has several strengths. We have demonstrated the feasibility of using routinely collected health administrative data to understand the breast cancer diagnostic process. Our approach provides methodological guidance for determining breast cancer detection method, diagnostic interval and use of specialized breast diagnostic assessment units that may be adapted for use over time in Ontario and in other Canadian provinces. This is the first Ontario study to provide population-based evidence on the breast cancer screening detection rate, diagnostic interval and use Note: -indicates cells with counts less than 10, which were not reported due to ICES privacy regulations.
a Calculated as the percent of patients diagnosed through DAU for each LHIN.
58.3% among breast cancer patients of all ages. This higher rate may be partly attributed to a more liberal definition of "screen-detected cancer": cancer diagnosed within 270 days of a bilateral (both breasts) screening mammogram.
Waiting for a diagnosis can have considerable psychological consequences for patients and their families and wait time reductions can significantly reduce anxiety levels. 6 In Canada, there is little guidance about breast cancer diagnostic wait times; breast cancer screening timeliness targets at the time of this study recommended that 90% of abnormal screenings should be resolved within 5 weeks, or within 7 weeks if a tissue biopsy is performed. 9 Applying the more liberal 7-week cut, we observed that 68.3% of breast cancer patients in our study were diagnosed within 7 weeks. Our observed rate is similar to a 64% rate reported in 2010 for resolution of all Ontario abnormal breast cancer screens requiring a tissue biopsy. 30 In our study, the median breast cancer diagnostic interval for Ontario in 2011 was 4.6 weeks (32 days), and 690 patients (10%) waited 3.6 months or longer, which is a level of delay that has been associated with worse survival. 8 Our observed median was shorter than the reported median time from an abnormal screen to diagnosis requiring tissue biopsy for other Canadian provinces in the year 2010 (range: 5-7 weeks). 30 This is likely explained by our restriction to the cancer population. We reported the diagnostic interval separately for the screen-detected and the symptomatic breast cancer patients in two companion papers, 14, 16 with medians of 29 days and 34 days, respectively. Our observations differed from findings in Alberta, which reported medians of 19 days for the screen-detected patients and 21 days for the symptomatic patients in the years 2004 to 2010. 25 Within Ontario, we observed significant regional variation in the diagnostic interval. The maximum difference was 2.4 weeks (17 days) between LHINs. Women who live in the North West, Central West and Mississauga Halton LHINs experienced the longest waits, exceeding 5 weeks. In 2011, the OBSP reported that these regions were among those that had the lowest 7-week tissue biopsy target rates. 3 Reasons for these low rates likely vary across these three LHINs as they are very different geographically and demographically. Further of diagnostic assessment units. This population-wide information highlighted the low screening detection rate (36%) when breast cancer patients of all ages are considered, and it provides a full picture of the breast cancer experience by including those who are opportunistically screened and those who presented symptomatically: groups who are routinely excluded from breast cancer diagnostic studies. Therefore, our findings provide a unique population perspective on the role of breast cancer screening in cancer detection, access to DAUs and the amount of time it takes for a diagnosis, which can inform cancer program policies and interventions and their evaluation. The geographic variations we observed provide important information for system administrators to compare across regions and identify successful regional initiatives for wider implementation. This information could prompt knowledge sharing and facilitate collaboration across regions aimed at improving the timeliness of care and, ultimately, patients' experience. The existence of such wide variation at a county level is a caution to other health care systems.
This study also has a number of limitations. First, we did not estimate the timeto-diagnosis or time-to-resolution interval for all patients being investigated for breast cancer, but instead focussed on the group who were ultimately diagnosed with the disease. Although patients under investigation are identifiable in the screening program, they are much harder to find in administrative data, which we needed in order to include patients who presented symptomatically. Evidence suggests that women with invasive breast cancer get a quicker diagnosis compared to those with benign diseases, 36, 37 so the intervals we report are likely shorter than the benign group would experience and therefore apply only to women with breast cancer.
Second, we did not have test results in the administrative databases, so a small portion of the 7.4% whom we considered as being opportunistically screened may have actually had a negative screening mammogram, making our estimate of their diagnostic interval longer than it actually was and erroneously labelling that small group as having been screendetected. Conversely, a small proportion of apparently symptomatic patients may have had an abnormal opportunistic screening test more than 6 months before diagnosis, thereby underestimating their
FIGURE 3
Length of diagnostic interval among breast cancer patients across counties, Ontario, Canada, 2011 Fourth, new physician billing codes that specify the reason for the mammogram (symptomatic vs. asymptomatic) were introduced on 1 October, 2010, and may not have been fully adopted by the time of our study. Therefore, some opportunistically screened patients may be misclassified as symptomatic and thus we may have underestimated the proportion of screendetected patients. We expect this influence to be small, because the frequency of use of this new code increased dramatically during the first three months of its introduction and had levelled off by the time of this study. 38 Finally, the determination of DAU use was subject to misclassification, with the sensitivity estimated at 90.1% and specificity at 84.6%.
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Conclusion
This report provides diagnostic access information about those who are ultimately diagnosed with a breast cancer. Among age-eligible breast cancer patients, we observed lower screening detection rates than screening participation rates in the general population. This result suggests that future cancer screening efforts should target women at increased risk of breast cancer and/or that the rate of interval cancers is in need of improvement. We also observed considerable variation in the length of diagnostic interval and DAU across geographic regions. There is a need for further research to understand the factors attributable to this variation and identify opportunities for system improvement. Finally, future efforts to understand diagnostic wait times and the influence of programs designed to mitigate them must occur at the population level rather than be restricted to organized screening programs. 
